228251-24-9

Basic information

• Product Name: 5-BROMO-2-CHLORO-PYRIDINE-3-CARBALDEHYDE
• Synonyms: 5-bromo-2-chloronicotinaldehyde (en);5-Bromo-2-chloropyridine-3-carboxaldehyde, 5-Bromo-2-chloro-3-formylpyridine;5-Bromo-2-chloro-3-pyridinecarboxaldehyde;5-BroMo-2-chloro-pyridine-3-carbaldehyde;3-Pyridinecarboxaldehyde,5-broMo-2-chloro-
• CAS NO: 228251-24-9
• Molecular Formula: C₆H₃BrClNO
• Molecular Weight: 220.46
• Mol File: 228251-24-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 278.003 °C at 760 mmHg
• Flash Point: 121.932 °C
• Appearance: /
• Density: 1.8 g/cm³
• Vapor Pressure: 0.00437mmHg at 25°C
• Refractive Index: 1.632
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.75±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-CHLORO-PYRIDINE-3-CARBALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-CHLORO-PYRIDINE-3-CARBALDEHYDE(228251-24-9)
• EPA Substance Registry System: 5-BROMO-2-CHLORO-PYRIDINE-3-CARBALDEHYDE(228251-24-9)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25
• Safety Statements: 45
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 228251-24-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-2-chloro-pyridine-3-carbaldehyde is a specialized chemical compound. It belongs to the group of pyridines, which are aromatic heterocyclic organic compounds similar to benzene and pyridine, with the formula C5H3BrClNO. This particular compound is identified with CAS number 884494-77-4. Its systematic name is 5-bromo-2-chloropyridine-3-carbaldehyde. Being a halogenated heterocyclic compound, it has bromine and chlorine as substituents, which might increase its chemical reactivity. It is typically used in research and development applications, in particular as a synthetic chemical intermediate in the preparation of other more complex compounds, including potential drug candidates and in material science. Like many substances of its kind, it should be handled with suitable protective measures as it may present unknown health hazards if improperly handled.

InChI:InChI=1/C6H3BrClNO/c7-5-1-4(3-10)6(8)9-2-5/h1-3H

Upstream product

• 78686-79-0 methyl 2-chloro-5-bromonicotinate 
• 29241-65-4 5-bromo-2-chloronicotinic acid 
• 885223-63-2 5-bromo-2-chloro-N-methoxy-N-methylnicotinamide 
• 742100-75-0 (5-bromo-2-chloro-pyridin-3-yl)-methanol 

Downstream Products

• 1111638-41-5 1-(5-bromo-2-chloropyridin-3-yl)ethanol 
• 1332392-76-3 5-bromo-2-chloro-3-(difluoromethyl)pyridine 
• 928653-74-1 5-bromo-2-chloro-3-(dimethoxymethyl)pyridine 

Relevant articles and documents

LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non alcoholic steatohepatitis (NASH).

PLASMA KALLIKREIN INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

CERTAIN PROTEIN KINASE INHIBITORS

Provided are certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.